Patients who discontinue GLP-1s found to have more weight gain, complications during pregnancyPatients who discontinue GLP-1s found to have more weight gain, complications during pregnancy
In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 Read More
Key immune differences in triple-negative breast cancer uncoveredKey immune differences in triple-negative breast cancer uncovered
Researchers at the LSU LCMC Health Cancer Center have published findings in npj Breast Cancer that shed new light on triple-negative breast cancer (TNBC), one of the most aggressive forms of breast cancer.
New Moms’ GLP-1 Prescriptions Jumped After Wegovy ApprovalNew Moms’ GLP-1 Prescriptions Jumped After Wegovy Approval
(MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study found. In the first quarter of 2018, there were less… (MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for Read More
Stopping GLP-1s for Pregnancy Linked to Weight Gain, ComplicationsStopping GLP-1s for Pregnancy Linked to Weight Gain, Complications
(MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and higher risks of pregnancy complications, according to an analysis of health records that primarily… (MedPage Today) — The recommended discontinuation of GLP-1 receptor agonists during pregnancy was associated with more gestational weight gain and Read More
How to Make Treatment Decisions in Breast Cancer Without Genomic AssaysHow to Make Treatment Decisions in Breast Cancer Without Genomic Assays
(MedPage Today) — In resource-limited settings, genomic assays for hormone receptor-positive, HER2-negative breast cancer aren’t always accessible. Yet treatment decisions still need to be made — often quickly and with limited information…
People who stop using Mounjaro tend to regain weight and lose other health benefits, says studyPeople who stop using Mounjaro tend to regain weight and lose other health benefits, says study
Improvements such as reduced ‘bad’ cholesterol and lower blood pressure go into reverse upon stopping weight-loss jabs People who stop using the weight-loss jab Mounjaro not only tend to regain weight, but experience a reversal in other health improvements too, research suggests. Mounjaro, which contains the active ingredient tirzepatide, has become a popular medication for Read More
STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaksSTAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review vouchers, and more. Can a GLP-1 drug slow Alzheimer’s Read More
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progressionSTAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as Read More
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event riskDulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with type 2 diabetes (T2DM). 2. All three agents were associated with an increased risk of gastrointestinal AEs, particularly motility-related events, compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2is). Evidence Rating Level: 2 (Good) Study Rundown: GLP-1 receptor Read More
Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial findsDaily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds
A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher. A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose Read More